propulsive

(redirected from Prokinetic)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
References in periodicals archive ?
A prokinetic agent like prucalopride may help to normalise movements .
Previous study showed that FRA possesses prokinetic, anti-dyspepsia, antiox-idative and anti-inflammatory effects (Huang et al.
And there are prokinetic agents such as metoclopramide, which also stimulate bowel muscles.
Medications used to treat GOR include acid-reducing agents such as ranitidine, proton-pump inhibitors such as omeprazole, and prokinetic agents such as domperidone, which elevate the lower oesophageal sphincter pressure and increase gastric emptying.
Metoclopramide, a prokinetic drug used for more than 40 years to treat nausea and vomiting due to various causes, is one alternative to the doxylamine-pyridoxine combination.
Prokinetic drugs like cisapride, mosapride, metoclopramide, erythromycin and domperidone have been used to overcome morphine-induced gastrointestinal delay.
2,6,7) A prokinetic agent may be added to the regimen if dysphagia is present or if initial therapy with a proton-pump inhibitor is less successful than expected.
docusate sodium and calcium) * Prokinetic agent: erythromycin * Enemas: phosphate enema and sodium citrate enema) Nonpharmacologic Interventions * Activity or increased mobility * Aromatherapy, massage therapy, and aromatherapy massage * Biofeedback * Dietary fiber * Fresh baker's yeast * Herbal supplements * Paraffin * Seeds dils or arachisoil * Stercullia (type of fiber) Note.
Nonetheless, expert opinion tells us that we should be employing drugs such as proton-pump inhibitors, prokinetic agents, and antibiotics for bacterial overgrowth," he said.
Prokinetic agents include metoclopramide (also known as Reglan), bethanechol (Duvoid) and tegaserod (Zelnorm).
Delayed gastric emptying due to gastroparesis is managed by dietary adjustments, prokinetic medications, avoidance of medications that retard gastric motor activity and optimizing glycemic control in diabetic patients.
Said James Bristol, senior vice president, Pfizer World Wide Discovery Research, "Pfizer believes that the mechanism of action of KOS-2187 and its demonstrated activity as a prokinetic agent are significant indications of its potential as a new approach for the treatment of gastrointestinal diseases.